Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
C. Thibeault,
B. Mühlemann,
E. Helbig,
M. Mittermaier,
T. Lingscheid,
P. Tober-Lau,
L. Meyer-Arndt,
L. Meiners,
P. Stubbemann,
S. Haenel and
others,
"Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study",
Infection,
vol. 49,
no. 4,
pp. 703—714,
2021.
| DOI: | 10.1007/s15010-021-01594-w |
C. Thibeault and
et al,
"Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study",
Infection,
2021.
| DOI: | 10.1007/s15010-021-01594-w |
A. Mikolajewska,
A. Fischer,
V. Piechotta,
A. Mueller,
M. Metzendorf,
M. Becker,
E. Dorando,
R. L. Pacheco,
A. L. C. Martimbianco,
R. Riera,
N. Skoetz and
M. Stegemann,
"Colchicine for the treatment of COVID‐19",
Cochrane Database of Systematic Reviews,
vol. 2021,
pp. CD015045,
2021.
| DOI: | 10.1002/14651858.CD015045 |
M. Ochs,
S. Timm,
S. Elezkurtaj,
D. Horst,
J. Meinhardt and
e. a. Heppner,
"Collapse induration of alveoli is an ultrastructural finding in a COVID-19 patient",
Eur Respir J,
vol. 57,
2021.
| DOI: | 10.1183/13993003.02311-2020 |
K. Herbst,
M. Meurer,
D. Kirrmaier and
others,
"Colorimetric RT-LAMP and LAMP-sequencing for Detecting SARS-CoV-2 RNA in Clinical Samples",
BIO-Protocols,
vol. 11,
no. 6,
2021.
| DOI: | 10.21769/BioProtoc.3964 |
| Datei: | https://doi.org/10.21769/BioProtoc.3964 |
L. Brunotte,
S. Zheng,
A. Mecate-Zambrano,
J. Tang,
S. Ludwig and
e. a. Rescher,
"Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro",
Pharmaceutics,
vol. 13,
2021.
A. Müller,
F. Engler,
D. Schütze,
P. Nohl-Deryk and
C. Güthlin,
"Communication experience by secure instant messaging during the Covid-19 pandemic for general practitioners and public health workers – a qualitative analysis",
Doc21dkvf051,
2021.
| DOI: | 10.3205/21dkvf051 |
A. Osterman,
M. Iglhaut,
A. Lehner and
et al,
"Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern",
Med Microbiol Immunol,
vol. 210,
2021.
| DOI: | 10.1007/s00430-021-00719-0 |
A. Osterman,
M. Iglhaut,
A. Lehner,
P. Späth,
M. Stern,
H. Autenrieth,
M. Muenchhoff,
A. Graf,
S. Krebs,
H. Blum,
A. Baiker,
N. Grzimek-Koschewa,
U. Protzer,
L. Kaderali,
H. Baldauf and
O. T. Keppler,
"Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern",
Medical microbiology and immunology,
vol. 210,
no. 5-6,
pp. 263—275,
2021.
Abstract:
A versatile portfolio of diagnostic tests is essential for the containment of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Besides nucleic acid-based test systems and point-of-care (POCT) antigen (Ag) tests, quantitative, laboratory-based nucleocapsid Ag tests for SARS-CoV-2 have recently been launched. Here, we evaluated four commercial Ag tests on automated platforms and one POCT to detect SARS-CoV-2. We evaluated PCR-positive (n = 107) and PCR-negative (n = 303) respiratory swabs from asymptomatic and symptomatic patients at the end of the second pandemic wave in Germany (February-March 2021) as well as clinical isolates EU1 (B.1.117), variant of concern (VOC) Alpha (B.1.1.7) or Beta (B.1.351), which had been expanded in a biosafety level 3 laboratory. The specificities of automated SARS-CoV-2 Ag tests ranged between 97.0 and 99.7% (Lumipulse G SARS-CoV-2 Ag (Fujirebio): 97.03%, Elecsys SARS-CoV-2 Ag (Roche Diagnostics): 97.69%; LIAISONćircledR SARS-CoV-2 Ag (Diasorin) and SARS-CoV-2 Ag ELISA (Euroimmun): 99.67%). In this study cohort of hospitalized patients, the clinical sensitivities of tests were low, ranging from 17.76 to 52.34%, and analytical sensitivities ranged from 420,000 to 25,000,000 Geq/ml. In comparison, the detection limit of the Roche Rapid Ag Test (RAT) was 9,300,000 Geq/ml, detecting 23.58% of respiratory samples. Receiver-operating-characteristics (ROCs) and Youden's index analyses were performed to further characterize the assays' overall performance and determine optimal assay cutoffs for sensitivity and specificity. VOCs carrying up to four amino acid mutations in nucleocapsid were detected by all five assays with characteristics comparable to non-VOCs. In summary, automated, quantitative SARS-CoV-2 Ag tests show variable performance and are not necessarily superior to a standard POCT. The efficacy of any alternative testing strategies to complement nucleic acid-based assays must be carefully evaluated by independent laboratories prior to widespread implementation.
| DOI: | 10.1007/s00430-021-00719-0 |
Abstract:
A versatile portfolio of diagnostic tests is essential for the containment of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Besides nucleic acid-based test systems and point-of-care (POCT) antigen (Ag) tests, quantitative, laboratory-based nucleocapsid Ag tests for SARS-CoV-2 have recently been launched. Here, we evaluated four commercial Ag tests on automated platforms and one POCT to detect SARS-CoV-2. We evaluated PCR-positive (n = 107) and PCR-negative (n = 303) respiratory swabs from asymptomatic and symptomatic patients at the end of the second pandemic wave in Germany (February-March 2021) as well as clinical isolates EU1 (B.1.117), variant of concern (VOC) Alpha (B.1.1.7) or Beta (B.1.351), which had been expanded in a biosafety level 3 laboratory. The specificities of automated SARS-CoV-2 Ag tests ranged between 97.0 and 99.7% (Lumipulse G SARS-CoV-2 Ag (Fujirebio): 97.03%, Elecsys SARS-CoV-2 Ag (Roche Diagnostics): 97.69%; LIAISONćircledR SARS-CoV-2 Ag (Diasorin) and SARS-CoV-2 Ag ELISA (Euroimmun): 99.67%). In this study cohort of hospitalized patients, the clinical sensitivities of tests were low, ranging from 17.76 to 52.34%, and analytical sensitivities ranged from 420,000 to 25,000,000 Geq/ml. In comparison, the detection limit of the Roche Rapid Ag Test (RAT) was 9,300,000 Geq/ml, detecting 23.58% of respiratory samples. Receiver-operating-characteristics (ROCs) and Youden's index analyses were performed to further characterize the assays' overall performance and determine optimal assay cutoffs for sensitivity and specificity. VOCs carrying up to four amino acid mutations in nucleocapsid were detected by all five assays with characteristics comparable to non-VOCs. In summary, automated, quantitative SARS-CoV-2 Ag tests show variable performance and are not necessarily superior to a standard POCT. The efficacy of any alternative testing strategies to complement nucleic acid-based assays must be carefully evaluated by independent laboratories prior to widespread implementation.
P. Georg and
et al,
"Complement activation induces excessive T cell cytotoxicity in severe COVID-19",
Cell,
2021.
| DOI: | 10.1016/j.cell.2021.12.040 |
P. Georg,
R. Astaburuaga-García,
L. Bonaguro and
et al,
"Complement activation induces excessive T cell cytotoxicity in severe COVID-19",
Cell,
2021.
| DOI: | 10.1016/j.cell.2021.12.040 |
B. Föh,
M. Borsche,
A. Balck and
et al,
"Complications of nasal and pharyngeal swabs – a relevant challenge of the COVID-19 pandemic?",
Eur Respir J,
2021.
| DOI: | 10.1183/13993003.04004-2020 |
V. Piechotta,
C. Iannizzi,
K. L. Chai,
S. J. Valk,
C. Kimber,
E. Dorando,
I. Monsef,
E. M. Wood,
A. A. Lamikanra,
D. J. Roberts,
Z. McQuilten,
C. So-Osman,
L. J. Estcourt and
N. Skoetz,
"Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review",
Cochrane Database of Systematic Reviews,
vol. 2021,
pp. CD013600,
2021.
| DOI: | 10.1002/14651858.CD013600.pub4 |
F. Beierle and
et al,
"Corona Health—A Study- and Sensor-Based Mobile App Platform Exploring Aspects of the COVID-19 Pandemic",
Int J Environ Res Public Health,
vol. 18,
pp. 7395,
2021.
| DOI: | 10.3390/ijerph18147395 |
S. Steudte-Schmiedgen,
L. Stieler,
Y. Erim,
E. Morawa,
F. Geiser,
P. Beschoner,
L. Jerg-Bretzke,
N. Hiebel and
K. Weidner,
"Correlates and Predictors of PTSD Symptoms Among Healthcare Workers During the COVID-19 Pandemic: Results of the egePan-VOICE Study",
Frontiers in Psychiatry,
vol. 12,
2021.
| DOI: | 10.3389/fpsyt.2021.686667 |
| Datei: | https://doi.org/10.3389/fpsyt.2021.686667 |
A. Ebigbo,
C. Römmele,
C. Bartenschlager and
et al,
"Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment",
Endoscopy,
vol. 53,
no. 2,
2021.
| DOI: | 10.1055/a-1294-0427 |
M. Baumann,
"COVID-19 and mental health in children and adolescents: a diagnostic panel to map psycho-social consequences in the pandemic context",
Discov Ment Health,
vol. 1,
no. 1,
pp. 2,
2021.
| DOI: | 10.1007/s44192-021-00002-x |
N. Ritschel,
H. Radbruch,
C. Herden,
N. Schneider,
C. Dittmayer and
e. a. Franz,
"COVID-19 and the central and peripheral nervous system",
Pathologe,
vol. 42,
pp. 172—182,
2021.
| DOI: | 10.1007/s00292-021-00923-w |
Q. Ul Ain,
A. Hocke and
S. Hedtrich,
"COVID-19 highlights the model dilemma in biomedical research",
Nat Rev Mater,
pp. 1—3,
2021.
W. Roth and
P. Boor,
"COVID-19 im Spiegel der Pathologie [COVID-19 in the mirror of pathology]",
Pathologe,
vol. 42,
no. 2,
pp. 147-148,
2021.
E. Gaitzsch and
et al,
"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma",
HemaSphere,
vol. 5,
pp. e603,
2021.
| DOI: | 10.1097/HS9.0000000000000603 |
E. Gaitzsch,
V. Passerini,
E. Khatamzas and
et al,
"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma",
Hemasphere,
vol. 5,
no. 7,
2021.
| DOI: | 10.1097/HS9.000000000000060 |
S. Heinemann,
A. Bludau,
H. Kaba and
et al,
"COVID-19 surveillance and testing strategies für patiens in German hospitals – results from a cross-sectional study",
DGHM,
2021.
| Datei: | https://www.egms.de/static/de/journals/dgkh/2021-16/dgkh000402.shtml |
A. Bludau,
M. Anton,
S. Heinemann and
et al,
"COVID-19 vaccination and immunization surveillance for employees in German hospitals – results from a cross-sectional study",
DGHM,
2021.
| Datei: |  https://www.dghm-kongress.de/fileadmin/congress/media/dghm2021/pdf/DGHM_2021_digital_Programme_booklet.pdf |
R. Tanacli,
P. Doeblin,
C. Götze,
V. Zieschang,
A. Faragli,
C. Stehning,
G. Korosoglou,
J. Erley,
J. Weiss,
A. Berger and
others,
"COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy",
Front Cardiovasc Med,
vol. 8,
pp. 737257,
2021.
| DOI: | 10.3389/fcvm.2021.737257 |
P. Boor,
T. Wiech,
J. Singh,
E. Vonbrunn,
A. Knöll,
M. Hermann,
M. Büttner-Herold,
C. Daniel and
A. Hartmann,
"COVID-19-Auswirkungen auf die Niere [COVID-19 effects on the kidney]",
Pathologe,
vol. 42,
no. 2,
pp. 183-187,
2021.
C. Seeber,
M. Popp,
J. J. Meerpohl and
et al,
"COVID-19-Pandemie: Präferenzen und Barrieren für die Disseminierung von Evidenzsynthesen",
Anaesthesist,
2021.
| DOI: | 10.1007/s00101-021-01037-z |
K. Polotzek,
A. Karch,
J. Karschau,
M. Wagner,
B. Lünsmann,
M. Menk,
C. Römmele and
J. Schmitt,
"COVID-19-Pandemie: Regionale Steuerung der Patienten",
Dtsch Arztebl International,
vol. 118,
no. 3,
pp. 84—,
2021.
N. Ritschel,
H. Radbruch,
C. Herden,
N. Schneider and
et al,
"COVID-19: Auswirkungen auf das zentrale und periphere Nervensystem",
Pathologe,
vol. 42,
pp. 172-182,
Mä.
2021.
| DOI: | https://doi.org/10.1007/s00292-021-00924-x |
C. Werlein,
F. Länger,
M. P. Kühnel and
D. D. Jonigk,
"COVID-19: Auswirkungen auf Lunge und Herz [COVID-19: effects on the lungs and heart]",
Pathologe,
vol. 42,
no. 2,
pp. 164-171,
2021.
L. Loyal,
J. Braun,
L. Henze,
B. Kruse,
M. Dingeldey and
e. a. Reimer,
"Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon infection and vaccination",
Science,
2021.
L. Loyal and
et al,
"Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination",
Science (New York, N.Y.),
2021.
| DOI: | 10.1126/science.abh1823 |
M. Metzendorf,
"Das Cochrane COVID-19 Studienregister – eine studienbasierte, strukturierte Datenbank zur effizienten Identifizierung wissenschaftlicher Evidenz",
GMS Med Bibl Inf,
vol. 21,
no. 1-2,
pp. Doc09,
Sep.
2021.
| DOI: | 10.3205/mbi000498 |
C. Edler,
A. Klein,
A. Schröder,
J. Sperhake and
B. Ondruschka,
"Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®)",
Leg Med (Tokyo),
vol. 51,
pp. 101895,
Jul.
2021.
| DOI: | 10.1016/j.legalmed.2021.101895 |
J. Trimpert and
et al,
"Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters",
Viruses,
vol. 13,
2021.
| DOI: | 10.3390/v13112290 |
M. Schwabenland,
H. Salié,
J. Tanevski,
S. Killmer,
M. Lago,
A. Schlaak,
L. Mayer,
J. Matschke,
K. Püschel,
A. Fitzek,
B. Ondruschka,
H. Mei,
T. Boettler,
C. Neumann-Haefelin,
M. Hofmann,
A. Breithaupt,
N. Genc,
C. Stadelmann,
J. Saez-Rodriguez,
P. Bronsert,
K. Knobeloch,
T. Blank,
R. Thimme,
M. Glatzel,
M. Prinz and
B. Bengsch,
"Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions",
Immunity,
vol. 54,
no. 7,
pp. 1594-1610.e11,
2021.
| DOI: | 10.1016/j.immuni.2021.06.002 |
T. Schwarz and
et al,
"Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany",
Emerging infectious diseases,
vol. 27,
2021.
| DOI: | 10.3201/eid2708.211145 |
N. -. Hoff and
et al,
"Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction",
European Journal of Medical Research,
vol. 26,
pp. 98,
2021.
| DOI: | 10.1186/s40001-021-00557-z |
P. Arora and
et al,
"Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance",
Cellular & Molecular Immunology,
vol. 18,
pp. 2557—2559,
2021.
| DOI: | 10.1038/s41423-021-00772-y |
M. Baumann,
M. Berghäuser,
T. Bolz and
T. Martens,
"Den Fokus neu denken - Skizze eines Pandemiemanagements auf Grundlage der Bedürfnisse und Lern- und Entwicklungserfordernissen von Kindern, Jugendlichen und Familien",
2021.
J. Holz,
"Der Erfolg Vietnams im Kampf gegen das Virus",
Südostasien. Zeitschrift für Politik, Kultur, Dialog,
Feb.
2021.
M. Casagrande,
A. Fitzek,
M. Spitzer,
K. Püschel,
M. Glatzel,
S. Krasemann,
D. Nörz,
M. Lütgehetmann,
S. Pfefferle and
M. Schultheiss,
"Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19",
Br J Ophthalmol,
vol. 105,
no. 8,
pp. 1057-1061,
2021.
M. Döpfner,
C. Habbel and
et al,
"Die psychische Belastung von Kindern und Jugendlichen und ihren Familien während der COVID-19-Pandemie und der Zusammenhang mit emotionalen und Verhaltensauffälligkeiten",
Bundesgesundheitsbl,
vol. 64,
2021.
| DOI: | 10.1007/s00103-021-03455-1 |
M. Döpfner,
C. Habbel,
B. Schulte,
K. Schulze-Husmann,
M. Simons,
F. Heuer,
C. Wegner,
S. Bender,
B. Herpertz-Dahlmann and
others,
"Die psychische Belastung von Kindern, Jugendlichen und ihren Familien während der COVID-19-Pandemie und der Zusammenhang mit emotionalen und Verhaltensauffälligkeiten",
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz,
vol. 64,
no. 12,
pp. 1522—1532,
2021.
| DOI: | 10.1007/s00103-021-03455-1 |
A. Schuppert,
K. Polotzek,
J. Schmitt,
R. Busse,
J. Karschau and
C. Karagiannidis,
"Different spreading dynamics throughout Germany during the second wave of the COVID-19 pandemic: A time series study based on national surveillance data",
The Lancet Regional Health - Europe,
vol. 6,
pp. 100151,
2021.
| DOI: | 10.1016/j.lanepe.2021.100151 |
| Datei: | https://doi.org/10.1016/j.lanepe.2021.100151 |
R. J. Neumann,
B. Kollmann,
M. M. Plichta,
K. Lieb,
O. Tüscher and
A. Reif,
"Differential impact of COVID-related lockdown on mental health in Germany",
World Psychiatry,
vol. 20,
no. 1,
pp. 140—141,
2021.
| DOI: | 10.1002/wps.20830 |
K. Vanshylla and
et al,
"Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers",
Cell host & microbe,
2021.
| DOI: | 10.1016/j.chom.2021.12.010 |
S. Schlickeiser,
T. Schwarz,
S. Steiner,
K. Wittke,
O. Meyer,
U. Kalus,
A. Pruß,
F. Kurth,
T. Zoller and
others,
"Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses",
Front Immunol,
vol. 11,
pp. 628971,
2021.
| DOI: | 10.3389/fimmu.2020.628971 |
F. Heinrich,
C. Romich,
T. Zimmermann,
I. Kniep,
A. Fitzek,
S. Steurer,
M. Glatzel,
D. Nörz,
T. Günther,
M. Czech-Sioli,
N. Fischer,
A. Grundhoff,
M. Lütgehetmann and
B. Ondruschka,
"Dying of VOC-202012/01 - multimodal investigations in a death case of the SARS-CoV-2 variant",
Int J Legal Med,
pp. 1-10,
2021.
| DOI: | 10.1007/s00414-021-02618-8 |
S. Deinhardt-Emmer,
D. Wittschieber,
J. Sanft,
S. Kleemann,
S. Elschner and
e. a. Haupt,
"Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage",
Elife,
vol. 10,
2021.